Enduracin - instructions for use, dose, side effects, contraindications

Enduracin is a new tabletted form of nicotinic acid on a wax matrix that allows nicotinic acid to be evenly released and absorbed within 6-8 hours as the tablet passes through the gastrointestinal tract, thereby increasing the effectiveness of the drug and reducing the number of possible side effects.

Nicotinic acid is a biologically active substance involved in various metabolic processes occurring in the human body. In small doses a nicotinic acid acts as a vitamin, in large doses is an effective antiatherosclerotic. A nicotinic acid expands blood vessels, especially small ones, increases blood flow at the level of microcirculation, has a weak anticoagulant effect.

Pharmacokinetics:After taking the drug inside absorbed from the gastrointestinal tract (GIT) for 6 to 8 hours.During the first hour about 50% of the drug is absorbed, by the eighth hour - about 96%. The drug is metabolized in the body and excreted by the kidneys.

Indications:

In complex therapy

- chronic ischemic heart disease (a condition after myocardial infarction, unstable angina, atherosclerotic cardio, stable exertional angina and rest);

- cerebrovascular insufficiency;

- violations of lipid metabolism (including in the absence of clinical manifestations of the disease):

■ hypercholesterolemia - total cholesterol blood concentration of 200-300 mg / dl (5,2-7,8 mmol / l);

■ hypertriglyceridemia - blood triglyceride concentration of 200-400 mg / dl (2 .3- 4.6 mmol / l);

■ hypoalpha cholesterolemia - HDL cholesterol less than 35 mg / dL (less than 0.9 mmol / l).

Contraindications:

Increased individual sensitivity to the drug, gastric ulcer and duodenal ulcer, gout, diabetes, pregnancy, lactation, infancy, chronic hepatitis and cirrhosis of any origin, severe hypertension, hyperuricemia, nephrolithiasis.

Carefully:hemorrhage, hyperacid gastritis.

Pregnancy and lactation:contraindicated

Dosing and Administration:

With ischemic heart disease, the drug is prescribed in an initial dose of 500 mg / day. (1 tablet) per day during the first week of treatment, then 1000 mg / day a day (1 tablet in the morning and in the evening) during the second week and, starting from the third week of treatment, 3 tablets per day (1500 mg / day ).

After three months of treatment, it is necessary to conduct a biochemical blood test (lipids, transaminases, alkaline phosphatase, glucose, uric acid). With insufficient therapeutic effect, treatment should be continued in a dose of 4-6 tablets (2000-3000 mg) per day for 1 to 2 months. At achievement of therapeutic effect it is possible to make monthly break in treatment and after it to repeat a course of reception of a preparation within 2,5 - 3 months.

Typically, the average daily dose of Enduracin is 1500 -2000 mg.

The maximum daily dose of the drug is 3000 mg.

With cerebrovascular insufficiency the drug is prescribed in an initial dose of 500 mg / day. (1 tablet) per day during the first week of treatment, then 1000 mg / day. (1 tablet in the morning and in the evening) a day for the second week and, starting from the third week of treatment, 3 tablets (1500 mg / day) per day.After three months of treatment, it is necessary to conduct a biochemical blood test (lipids, transaminases, alkaline phosphatase, glucose, uric acid). With insufficient therapeutic effect, treatment should be continued at a dose of 4-6 tablets (2000-3000 mg) per day for 1-2 months. When the therapeutic effect is achieved, you can make a one-month break in treatment and after it repeat the course of taking the drug within 2.5 3 months.

The average daily dose of Enduracin is 1500 -2000 mg.

The maximum daily dose of the drug is 3000 mg.

In cases of lipid metabolism disorders, the drug is administered in doses:

- to increase the level of alpha cholesterol in isolated hypoalpha- cholesterolemia, the dose is 2 tablets (1000 mg) of enduracin per day;

- with moderate dyslipidemia in individuals with risk factors, take 1-2 tablets (500-1000 mg) of enduracin per day.

Tablets should be taken during or after meals, with integrity preserved (do not break and not chew), drink with a small amount of non-corrosive liquid.

Side effects:

Allergic reactions, redness of the face, dry skin, itching or burning sensation, headache,exacerbation of peptic ulcer of the stomach and duodenum, transient increase in the activity of transaminases, glucose and uric acid concentrations in the blood plasma, paresthesia, dizziness, arrhythmia, orthostatic hypotension, diarrhea, myalgia, nausea, vomiting.

With long-term use - fatty liver disease, decreased glucose tolerance, increased concentration in the blood of LDH, ЩФ, asthenia.

Interaction:

Care must be taken when concomitantly administering enduracin with antihypertensive agents, acetylsalicylic acid, anticoagulants due to the potential for enhancing the effect of these drugs.

At simultaneous application with lipid-lowering agents of other groups, the risk of toxic effects of enduracin may be increased.

Special instructions:

During the treatment with the drug it is necessary to conduct regular medical examination (1 time in 2 months).

To achieve therapeutic effect, a gradual increase in the dose of the drug is necessary.

Controlling plasma cholesterol should be done at least once every 3-6 months.

With the development of adverse reactions, it is recommended to reduce the dose of the drug or to suspend treatment.After 3-7 days, it is possible to resume therapy in a reduced dose.

Effect on the ability to drive transp. cf. and fur:

Long-acting tablets 500 mg.

For 30 or 100 tablets in white opaque polymer bottles with a membrane and a white screwed polymer cover; the instructions for use are labeled on the label.

Packaging:(100) - polymer bottles
(30) - polymer bottles

Storage conditions:

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

Shelf life 5 years.

Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:П N011477 / 01

Date of registration:14.03.2008

The owner of the registration certificate:Endurans Products Co.Endurans Products Co. USA

Manufacturer: & nbsp

ENDURANCE PRODUCTS, Co USA

Representation: & nbspZITEKS, LLCZITEKS, LLC

Information update date: & nbsp13.08.2015

Illustrated instructions

Instructions

Enduracin (Endur-acin)